Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Exhaled Breath Test Discriminates COPD

By LabMedica International staff writers
Posted on 28 Jun 2017
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.

Analysis of exhaled breath by real-time mass spectrometry helps discriminate between patients with chronic obstructive pulmonary disease (COPD), healthy controls, and patients with asthma. COPD is presently diagnosed based upon airflow restriction in spirometry, respiratory symptoms, and history of exposure to risk factors.

Scientists at the University Hospital Zurich (Switzerland) compared 49 patients with COPD whose mean age was 64 years 59.2% were male; 53 healthy control subjects whose mean age was 43 years and 52.8%were female, and 31 patients with asthma whose mean age was 41 years and 64.5% were male. The team used secondary electrospray ionization/high-resolution mass spectrometry to define a series of potential markers in exhaled breath with the potential to discriminate patients with COPD from healthy controls.

The team identified 57 specific COPD discriminatory markers, with a further 56 that overlapped with the control subjects, and 17 with the subjects with asthma, all 17 of which were common to all of these patients. Identification of 23 compounds using real-time mass spectrometry that best defined signals significantly correlated with forced expiratory volume in one second predicted (FEV1%-predicted) in terms of the FEV1/ forced vital capacity (FVC-predicted) ratio. These compounds generally belong to the oxidative stress cascade and the lipolysis cascade. Patients with COPD showed FEV1 44.6, FVC 75.8, and FEV1/FVC ratio of 44. The healthy control subjects showed FEV1 101.2, FVC 105.3, and FEV1/FVC ratio of 81. Patients with asthma had FEV1 84.4, FVC 99.5, and FEV1/FVC ratio of 70.

Yvonne Nussbaumer-Ochsner, MD, the lead author, said, “There are more biomarkers overlapping with the control group than with asthma, which is actually also a kind of chronic obstructive airways disorder. Asthmatics appear to have different biomarkers in their exhaled breath compared with both controls and patients with COPD.” The study was presented on June 8, 2017, at the Joint CHEST-Swiss Society of Pneumology Congress (CHEST-SGP) held in Basel, Switzerland.

Related Links:
University Hospital Zurich


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.